Filing identity and reporting period
Important identity discrepancy: The request names Neurogene Inc., but the supplied Form 10-Q is for Aquinox Pharmaceuticals, Inc. (Nasdaq-listed; commission file no. 001-36327). Confirm that this is the intended filing before relying on this summary. The report covers the quarter and six months ended June 30, 2015; financial statements are unaudited and amounts below are U.S. dollars.
Aquinox was a clinical-stage pharmaceutical company focused on SHIP1-targeting therapeutics. Its lead candidate, AQX-1125, was being developed for bladder pain syndrome/interstitial cystitis (BPS/IC) and atopic dermatitis (AD). The company had no product revenue.
Financial position and results
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $3.619 million | $8.186 million | $4.551 million and $6.431 million |
| General and administrative expense | $1.173 million | $2.646 million | $1.081 million and $1.816 million |
| Total operating expenses | $4.792 million | $10.832 million | $5.632 million and $8.247 million |
| Net loss | $4.750 million | $11.162 million | $5.424 million and $9.653 million |
| Basic and diluted net loss per share | $0.44 | $1.04 | $0.51 and $1.43 |
| Cash used in operating activities | Not separately stated | $12.098 million | $6.609 million used |
Quarterly operating expenses declined about 15% year over year, and quarterly net loss narrowed about 12%. For the first half, operating expenses rose about 31% and net loss widened about 16%; management attributed higher R&D costs to having three clinical trials underway versus two in the prior-year period. No operating margin is meaningful because the company had no revenue.
At June 30, 2015, cash and cash equivalents were $14.916 million and short-term investments were $14.109 million, totaling approximately $29.0 million in liquid funds. Working capital was $25.8 million; total assets were $29.859 million, total liabilities $4.049 million, and accumulated deficit $100.577 million. Accounts payable and accrued liabilities were $3.983 million. The SVB term loan had been fully repaid in March 2014; the filing reports no outstanding loan principal at quarter-end. A $66,000 warrant derivative liability remained.
First-half investing activities provided $12.088 million, primarily from investment maturities; financing activities provided $20,000, mainly reflecting option exercises net of offering costs. Cash and cash equivalents increased by $10,000 during the half-year. The filing reports no off-balance-sheet arrangements.
Material changes and operating developments
- First-half operating cash use increased to $12.1 million from $6.6 million in the comparable 2014 period, driven by clinical development spending.
- Leadership Phase 2 BPS/IC trial results, announced June 25, showed a 2.4-point mean pain-score reduction with AQX-1125 versus 1.3 points with placebo at six weeks; the difference did not reach statistical significance (p=0.061). Secondary measures were described as consistently favorable. The company said treatment was generally well tolerated, with no serious adverse events reported.
- Flagship Phase 2 COPD results, announced July 9 after quarter-end, showed no efficacy on the primary symptom measure or the secondary medically treated exacerbation endpoint. The company said it did not plan further COPD development. Adverse-event rates were similar to placebo.
- Enrollment in the Kinship Phase 2 AD trial was completed in May. Top-line results were expected in the fourth quarter of 2015.
- G&A increased year over year for the first half, which management attributed mainly to public-company costs following the March 2014 IPO. First-half foreign-exchange losses also contributed to other expenses.
Outlook, risks and contingencies
Management said existing capital resources were sufficient to support operations for the next 12 months, but substantial additional financing would be needed thereafter. Future equity or convertible-debt financing might dilute shareholders or impose senior rights or restrictive covenants; availability on acceptable terms was not assured. The company expected significant losses and expenses to continue and had not provided revenue or earnings guidance.
Key risks include dependence on AQX-1125 and successful clinical and regulatory outcomes; the Leadership trial’s failure to meet statistical significance and the negative COPD result; the unvalidated SHIP1 target; clinical-trial, safety, manufacturing and regulatory uncertainty; reliance on third-party research organizations and manufacturers; and the need for future capital. The filing also identifies foreign-currency exposure and states that the company did not hedge it. It estimated that a 100-basis-point interest-rate increase would reduce investment fair value by approximately $0.05 million.
The company reported no material legal proceedings and no material changes to previously disclosed contractual commitments. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material quarterly change in internal control over financial reporting. The filing disclosed prior significant deficiencies in internal controls and noted that remediation and public-company compliance remained important considerations.
Most important facts for investors to verify
- Whether this Aquinox 10-Q is actually the intended filing, given the Neurogene Inc. company name in the request.
- The full Leadership trial data and regulatory feedback on whether and how to proceed with pivotal BPS/IC studies, given the primary endpoint was not statistically significant.
- Kinship trial top-line results, expected in Q4 2015, and their effect on development plans.
- Actual cash consumption and financing needs against management’s stated 12-month runway; the runway is a forward-looking estimate.
- Progress on internal-control remediation, clinical supply arrangements, and any financing or share issuance that could affect liquidity or dilution.